Entries by Maren Kühr

Enzymatica CEO steps down

The CEO of Lund-based Enzymatica AB, Claus Egstrand, is stepping down from his role. CFO Therese Filmersson will also leave her position. The process of finding their successors has already begun.

Unlocking Pichia for industry

Pichia pastoris (syn. Komagataella phaffii), a methylotrophic yeast, is a proven platform for pharmaceutical protein production. However, its potential reaches far beyond. As a reliable, scalable, and cost-efficient platform for recombinant protein expression, Pichia is equally suited for industrial enzymes, food & feed, diagnostics, and biomaterials.

Ensuring flexibility and resilience

In today’s rapidly evolving world, adapting to demand volatilities while ­ensuring uninterrupted supply of biological medicines is more critical than ever. At ­Boehringer Ingelheim, our global biopharmaceutical network delivers flexibility, resilience, and ­reliability. By leveraging harmonised procedures, standardised setups, and innovative logistics, we ­ensure the biologics we produce reach those in need – even during unexpected challenges.

US health care sector: rising demand with uncertainty

In addition to the uncertainty triggered by the US government with serious changes at the FDA and other healthcare institutions and an unclear stance of the US Secretary of Health and Human Services on various areas of innovation, the growing demand for health care services gives a positive momentum that can provide stability.

Closing the gap in Quality Management

In the life sciences industry, Quality Management (QM) has long been ­synonymous with compliance: checking boxes to meet regulatory demands. But that ­definition no longer holds up. Today, QM must do much more than ensure compliance; it needs to ­enable speed, scalability, and sustained innovation across complex, global operations. To do that, prominent gaps need to be filled.

Bayer Berlin develops a life sciences campus

It all began with a view from the window of the 15th floor of Bayer’s site in ­Berlin, reminiscent of Boston before it became one of the most important biotech hotspots in the world. This inspired the vision of developing the Bayer Campus into “Boston an der Spree” – a vibrant healthcare campus that fosters collaboration and innovation.

Why life sciences leaders need more than science

In life sciences, breakthroughs are reshaping healthcare faster than ever. But true leadership means going beyond the lab – understanding the complex ecosystem where ­science, policy, and business collide. For those struggling to navigate this complexity, WU ­Vienna’s Executive MBA offers the insights and connections needed to stay ahead in an ­unpredictable industry.

Accelerating Europe’s Biotech Revolution

As the global race for biosolutions intensifies, Europe is at a critical crossroads, and I am deeply concerned about the future of our continent’s biotech industry. While countries like China and the United States rapidly advance their biotech industries, Europe’s slow and not up-to-date regulatory system poses a significant risk to maintaining our leadership.

New CEO – new chapter

MC2 Therapeutics A/S, a Hørsholm-based pharmaceutical company focused on topical therapies in inflammatory skin conditions, announced the appointment of Trine Ahlgreen as Chief Executive Officer at the end of May.